George Stephen Eisenbarth
Physician in Denver, CO
License number
Colorado 31869
Issued Date
Jul 16, 1992
Renew Date
Jun 1, 2011
Expiration Date
Apr 30, 2013
Type
Physician
Address
Address
1775 Aurora Ct Ste B140 Barbara Davis Ctr STE B140, Denver, CO 80045
Professional information
Dr. George Eisenbarth, Aurora CO - MD (Doctor of Medicine)
Specialties:
Endocrinology, Diabetes & Metabolism, Endocrinology & Metabolism
Address:
Barbara Davis Center
1775 Aurora Ct STE 1324, Aurora 80045
(303) 724-2323 (Phone)
1775 Aurora Ct STE 1324, Aurora 80045
(303) 724-2323 (Phone)
Certifications:
Diabetes, Metabolism & Endocrinology, 1979, Internal Medicine, 1978
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Duke University
Duke University Hospital
Natl Inst Hlth
Duke University
Duke University Hospital
Natl Inst Hlth
George S Eisenbarth, Aurora CO
Specialties:
Pediatrician
Address:
1775 Aurora Ct, Aurora, CO 80045
Education:
Duke University, School of Medicine - Doctor of Medicine
National Institutes of Health-Clinical Center - Fellowship - Endocrinology
Duke University Hospital - Residency - Endocrinology
Duke University Hospital - Residency - Family Medicine
National Institutes of Health-Clinical Center - Fellowship - Endocrinology
Duke University Hospital - Residency - Endocrinology
Duke University Hospital - Residency - Family Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Endocrinology and Metabolism (Internal Medicine)
George Eisenbarth, Aurora CO
Work:
Barbara Davis Center
1775 Aurora Ct, Aurora, CO 80045
1775 Aurora Ct, Aurora, CO 80045
Methods For Detecting Insulin Autoantibody
US Patent:
2013001, Jan 10, 2013
Filed:
Jan 6, 2011
Appl. No.:
13/521023
Inventors:
George S. Eisenbarth - Golden CO, US
Liping Yu - Centennial CO, US
Liping Yu - Centennial CO, US
Assignee:
The Regents of the University of Colorado - Denver CO
International Classification:
G01N 33/566, G01N 21/76, G01N 21/66, G01N 21/64
US Classification:
435 79, 436501
Abstract:
The present invention provides methods for detecting insulin autoantibody. Such methods can be used, for example, to predict susceptibility of and/or diagnose the presence of Type 1 diabetes in a subject. Some aspects of the invention also provide kits adapted for use in such methods. In particular, some aspects of the invention use proinsulin to detect the presence of insulin autoantibody.
Therapeutic Compositions And Methods For The Prevention Of Autoimmune Diseases
US Patent:
2012017, Jul 5, 2012
Filed:
Jun 3, 2010
Appl. No.:
13/376122
Inventors:
George Eisenbarth - Golden CO, US
Li Zhang - Aurora CO, US
John Kappler - Denver CO, US
Brian Stadinski - N. Easton MA, US
Li Zhang - Aurora CO, US
John Kappler - Denver CO, US
Brian Stadinski - N. Easton MA, US
International Classification:
A61K 39/395, A61P 3/10, C07K 16/18, A61K 39/385, A61P 37/04
US Classification:
4241391, 4241301, 4241931, 5303873, 5303879, 5303881, 5303891
Abstract:
The present invention is directed to therapeutic compositions and methods for the prevention or treatment of autoimmune diseases, comprising molecules that disrupt or prevent the assembly of the trimolecular complex required for the T cell immune response comprising the autoantigen, the MHC class II molecule, and the T cell receptor implicated in the autoimmune disease.
Compounds That Modulate Autoimmunity And Methods Of Using The Same
US Patent:
2012019, Aug 2, 2012
Filed:
Jun 4, 2010
Appl. No.:
13/376119
Inventors:
George Eisenbarth - Golden CO, US
Aaron Michels - Aurora CO, US
David Ostrov - Gainesville FL, US
Maki Nakayama - Denver CO, US
Aaron Michels - Aurora CO, US
David Ostrov - Gainesville FL, US
Maki Nakayama - Denver CO, US
International Classification:
A61K 31/44, A61K 31/663, A61K 31/194, A61K 31/198, A61K 31/351, A61P 3/10, A61K 31/47, A61K 31/4965, A61K 31/661, A61K 31/185, A61K 31/4172, A61P 37/06, A61K 31/662, A61K 31/222
US Classification:
4242781
Abstract:
The invention provides methods of preventing, treating or ameliorating autoimmune diseases such as diabetes by modulating the binding of MHC class II molecules to antigenic peptides or fragments of antigenic peptides of the autoimmune disease by the administration of small organic compounds. The invention also provides pharmaceutical compositions comprising the therapeutically effective small organic compounds and methods of using the same.